Magnesium- and Zinc-Substituted Beta-Tricalcium Phosphates As Potential Bone Substitute Biomaterials

摘要

A successful application of a calcium phosphate compound for bone repair in human was first reported by Albee in 1921 [1]. Albee described this compound as 'tricalcium phosphate'. In 1975, Nery et al [2] reported successful repair of a surgically created periodontal defect in dogs using a porous calcium phosphate compound described as tricalcium phosphate (TCP) prepared by Hubbard [3] by sintering a 'tricalcium phosphate' chemical reagent. Nery's 'TCP' was later shown by LeGeros, using x-ray diffraction, to consist of 20% beta-tricalcium phosphate (β-TCP), Ca_3(PO_4)_6 and 80% calcium hydroxyapatite, (HA), Ca_(10)(PO_4)_6(OH)_2 [4]. Nery subsequently renamed the compound, 'biphasic calcium phosphate' or BCP [5, 6, 7]. Development of commercial BCP products of varying HA/β-TCP ratios (e.g., 60/40, 20/80, 80/20) was based on the concept of preferential dissolution of the P-TCP component of the BCP [6,8].